Geropharm’s CEO, Pyotr Rodionov, discussed the company’s plan to introduce new medicines in Russia. The company has recently received a registration certificate for an Ozempic analogue and announced the registration of another generic drug from Novo Nordisk.
“This is also a new ultra-short insulin, we plan to register it in October this year, and from November it will be available to consumers. Next year we plan to introduce another short-acting insulin, glulisine, to the market. <…> Registration of a number of insulins may be completed at the end of 2024. That is, the entire line of insulins will be registered by us in the near future,” Rodionov said in an interview with TASS.
Furthermore, Geropharm has plans to register a drug in 2024 that stimulates platelet production. This drug is a generic version of a foreign medication known as romiplostim. Excitingly, the Russian company, Generium, recently unveiled their own domestic biosimilar named “Stimplate,” which contains the same active ingredient.
